Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)

Similar Items

• DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK
  od: Pollock, Richard F., i dr.
  Izdano: (2018)
• Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9)
  od: Pollock, Richard F., i dr.
  Izdano: (2019)
• Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)
  od: Pratley, Richard E., i dr.
  Izdano: (2019)
• Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK
  od: Thalange, Nandu, i dr.
  Izdano: (2019)
• Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
  od: Kawaguchi, Yuji, i dr.
  Izdano: (2019)